Key Points
- COO Lisa Miller sold 14,663 shares for about $215,253, a 5.5% reduction in her holdings. The sale covered tax withholding obligations tied to vested equity awards; she retained 251,904 shares.
- LifeStance beat quarterly estimates, reporting EPS of $0.06 versus $0.04 expected and revenue of $455.86 million, up 25.3% year over year.
- Analysts hold a “Moderate Buy” consensus rating with an average price target of $14.86; recent targets range up to $20 from BTIG Research.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) COO Lisa Miller sold 14,663 shares of LifeStance Health Group stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $14.68, for a total value of $215,252.84. Following the completion of the transaction, the chief operating officer directly owned 251,904 shares of the company's stock, valued at approximately $3,697,950.72. This trade represents a 5.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
LifeStance Health Group Stock Down 1.5%
Shares of NASDAQ:LFST opened at $14.15 on Friday. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 74.48 and a beta of 1.35. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.44 and a quick ratio of 1.44. The business's 50-day moving average is $12.77 and its 200-day moving average is $9.64. LifeStance Health Group, Inc. has a 1 year low of $6.01 and a 1 year high of $15.66.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The company had revenue of $455.86 million for the quarter, compared to analyst estimates of $431.59 million. The business's revenue was up 25.3% on a year-over-year basis. Equities research analysts predict that LifeStance Health Group, Inc. will post 0.18 earnings per share for the current year.
Institutional Trading of LifeStance Health Group
Several large investors have recently made changes to their positions in LFST. BlackRock Inc. bought a new stake in LifeStance Health Group in the 2nd quarter valued at about $389,293,000. Voya Investment Management LLC raised its stake in LifeStance Health Group by 1,249.6% during the 3rd quarter. Voya Investment Management LLC now owns 3,971,989 shares of the company's stock worth $47,783,000 after buying an additional 3,677,679 shares during the period. Wellington Management Group LLP bought a new position in LifeStance Health Group in the second quarter worth approximately $30,881,000. Jennison Associates LLC boosted its holdings in LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company's stock worth $65,157,000 after acquiring an additional 2,843,388 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in LifeStance Health Group by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company's stock worth $66,038,000 after acquiring an additional 1,461,215 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the company. JPMorgan Chase & Co. boosted their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research note on Thursday. Barclays raised their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Thursday, September 10th. BTIG Research lifted their price objective on shares of LifeStance Health Group from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Wall Street Zen downgraded shares of LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 5th. Finally, KeyCorp boosted their target price on shares of LifeStance Health Group from $15.00 to $17.00 and gave the company an "overweight" rating in a research report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $14.86.
Read Our Latest Analysis on LFST
About LifeStance Health Group
(
Get Free Report)
LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance's clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
